Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.
Koichi Azuma
No relevant relationships to disclose
Hiroshige Yoshioka
Honoraria - Chugai Pharma
Nobuyuki Yamamoto
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Chugai Pharma
Toshiaki Takahashi
No relevant relationships to disclose
Makoto Nishio
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer; Taiho Pharmaceutical
Nobuyuki Katakami
Honoraria - Chugai Pharma
Myung-Ju Ahn
No relevant relationships to disclose
Tomonori Hirashima
No relevant relationships to disclose
Makoto Maemondo
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Research Funding - Boehringer Ingelheim
Sang-We Kim
No relevant relationships to disclose
Masayoshi Noshiro
Employment or Leadership Position - Kyowa Hakko Kirin
Shiro Akinaga
Employment or Leadership Position - Kyowa Hakko Kirin
Keunchil Park
Consultant or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis; Lilly; Roche
Research Funding - AstraZeneca
Chun-Ming Tsai
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche
Tomohide Tamura
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Pfizer
Tetsuya Mitsudomi
Consultant or Advisory Role - Chugai Pharma; Kyowa Hakko Kirin; Roche
Kazuhiko Nakagawa
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma